U of Washington, VentriPoint to collaborate on heart disease database
VentriPoint Diagnostics has finalized a research and technology development agreement with the University of Washington to collaborate on projects that will broaden its VentriPoint Diagnostic System (VDS) commercial offering.
Under the terms of the agreement, the University of Washington in Seattle will expand its recruitment of global institutions to participate in building comprehensive databases of right and left ventricle reconstructions representing specific heart diseases, such as congenital heart disease (CHD), according to the Seattle-based VentriPoint.
The databases will be referenced by the VDS as it delivers 3D models and analysis of patients’ hearts based on anatomical points identified by doctors on 2D scans, the company said.
Under the agreement, the University of Washington will collaborate with VentriPoint to increase the size of the database used by the VDS by up to 160 additional CHD heart reconstructions of different conditions, according to the company. The University of Washington will also continue its transition of knowledge and processes to VentriPoint, in support of the technology license.
Under the terms of the agreement, the University of Washington in Seattle will expand its recruitment of global institutions to participate in building comprehensive databases of right and left ventricle reconstructions representing specific heart diseases, such as congenital heart disease (CHD), according to the Seattle-based VentriPoint.
The databases will be referenced by the VDS as it delivers 3D models and analysis of patients’ hearts based on anatomical points identified by doctors on 2D scans, the company said.
Under the agreement, the University of Washington will collaborate with VentriPoint to increase the size of the database used by the VDS by up to 160 additional CHD heart reconstructions of different conditions, according to the company. The University of Washington will also continue its transition of knowledge and processes to VentriPoint, in support of the technology license.